Phi Med Europe has conducted the clinical study “Widespread sensory neuropathy in diabetic patients hospitalized with severe Covid-19 infection”. This has recently been accepted to be published in “Diabetes Research and Clinical Practice“, the official journal of the International Diabetes Federation.
BHH member Phi Med Europe, founded in 2011 in Barcelona, is a medical technology company that has developed the innovative Quantitative Sensory Testing medical device NerveCheck. It has been used as a technology to detect neuropathy in patients with Covid-19. This was possible thanks to its characteristics as reliable, portable, quick and easy to use technology.